Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Core One Labs awaits patent for cost-effective biosynthetic psilocybin production system
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
Vocan Biotechnologies Inc., a subsidiary of Core One Labs Inc. (COOL) is days away from receiving a patent for its biosynthetic psilocybin production system, which is more efficient and significantly cheaper than conventional methods of extracting psilocybin. The proprietary system aims to produce a reliable product that is consistent in quality and concentration while remaining comparable to naturally occurring psilocybin. Core One believes that there is a wide appeal for biosynthetic production as the psychedelics market grows, as “the need for a steady and consistent supply chain will also increase”.
Mom finds relief from post-partum depression through microdosing
Using Psychedelic Plants as Medicine – A New Solution for Mental Health Disorders
After having her second child, Melissa Lavasani became so severely depressed that she could barely function. She finally found relief through microdosing psilocybin. “It was as if I was blind and deaf and could see colors and hear again. The quality of my life vastly improved”. She explained that there are no hallucinogenic effects with microdosing, rather “a feeling of empowerment” in which she felt well-rested and in control of her emotions.
Mydecine discovered more than 40 new compounds with medical potential in various mushroom species
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
Mydecine Innovations Group discovered over 40 new compounds with medical potential when screening 25 mushroom species. Mydecine’s senior scientist, Duff Sloley, said that chemical components in many species, especially the poisonous ones, have not been researched. Sloley explained that the compounds are very complex because they’ve evolved to protect the mushrooms from predators. “Since these compounds are evolved to affect biological systems and aspects of metabolic pathways, they stand a higher chance of proving to be useful pharmaceuticals”.
Field Trip Health Ltd. declares that it is a “world class company” by applying to list on the NASDAQ
Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market
After a successful listing on the TSX, Field Trip Health Ltd. applied to list on the NASDAQ Stock Exchange, which would allow US investors to support their growth. Field Trip executives state that this move declares to the public that they are a world class company, and that they are “positioned to be the global leader in the psychedelics industry”. Field Trip expects to commence with Phase 1 human trials of their proprietary psychedelic molecule by the end of 2021, and will have 20 health centers operating or under construction across the US, Canada, and Europe.
Cybin aims to treat COVID-related distress in frontline healthcare workers using new psychotherapy model
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
A new University of Washington study co-sponsored by Cybin aims to treat COVID-related depression, anxiety, burnout and post-traumatic stress in frontline healthcare workers using psychedelic-assisted psychotherapy. The study will test Cybin’s new transdiagnostic psychotherapy model called EMBARK, which is “aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics”. Cybin CEO Doug Drysdale says he considers it an honour to support the frontline workers who made great sacrifices for the public throughout the pandemic.
Study suggests that psilocybin therapy is at least as effective in treating depression as the leading antidepressant, but with fewer side effects and faster results
Psilocybin therapy appears to be at least as effective as a leading conventional antidepressant
A study suggests that psilocybin therapy is at least as effective in treating depression as the leading antidepressant, but with fewer side effects and faster results. After six weeks, participants receiving psilocybin therapy saw an 8.0 point reduction in depressive symptoms and reported “greater improvements in the ability to cry and feel compassion, intense emotion, and pleasure”. Participants receiving escitalopram, a leading SSRI antidepressant, saw just a 6.0 point reduction in depressive symptoms, and were more likely to experience side effects like anxiety, dry mouth, sexual dysfunction, and reduced emotional responsiveness.
Psychedelic “smart shops” to open in Jamaica
Psychedelic Mushroom Shops Reach The Americas
Many psychedelic companies are being drawn to Jamaica, one of the only countries where it’s legal to cultivate, extract, and sell psilocybin mushrooms. Silo Wellness is partnering with Mushe Inc. to open the first “smart shop” in the Western hemisphere, a psychedelic mushroom retail outlet that will sell functional and psychedelic mushrooms in various forms to locals and tourists.
Psyence Group formally began operations in Jamaica under its wholly owned subsidiary, Psyence Jamaica Ltd., which will focus on psilocybin treatment for patients in palliative care. To take on the new market, Psyence Jamaica is in collaboration with LONACAS Inc., a Jamaican clinical research company, and MycoMeditations, a “psilocybin wellness destination experience” in Treasure Beach, Jamaica.
Wake Network Inc. received clearance to conduct a “first-of-its-kind” clinical trial at a Jamaican university, which will study the effect of microdosing on depression and anxiety.
Why access to psilocybin therapy is still limited despite proven effectiveness
Why Is Ottawa Stalling Proven Magic Mushroom Therapy for the Dying?
After two psilocybin-assisted therapy sessions, a terminal cancer patient, Thomas Hartle, says that “ I can’t emphasize enough how much of my life it has given back. Even months later, it’s much easier for me to be able to clear my head of those useless, anxious thoughts.” While many patients like Hartle are having great success with psilocybin therapy, Canada’s bureaucratic application process is limiting the number of patients who can access it, with 119 exemption applications awaiting review. In order to administer psilocybin therapy effectively, it is crucial that medical professionals experience the drug for themselves, yet only 19 medical professionals have been granted access to it. CEO of TheraPsil, Spencer Hawkswell, says Health Canada is pushing for clinical trials before granting more exemptions, but these trials are incredibly labour-intensive, have strict criteria, and cost millions. Dr. Pam Kryskow of the Canadian Psychedelic Association is advocating to include psychedelic therapy as a palliative care option under Canada’s Medical Assistance in Dying legislation, which would allow terminal patients access to psilocybin without going through the slow application process. Krysow believes “that given their safety profile, given their efficacy, given how cheap they are… at this point it’s unethical to not be doing this.”
Government health official says feds should work with states to ensure equitable access to psychedelic therapy
Feds Should Work With—Not Against—States That Legalize Psychedelics, Government Health Official Says.
At a speaker series hosted by the National Institute of Health (NIH), government health official, Sean Belouin predicted that safety and ethical considerations of psychedelics reform “will rapidly become front-and-center regulatory and policy issues” as more states and municipalities follow Oregon in pursuing the medicalization and decriminalization of psychedelics. Belouin believes that the federal government and other stakeholders need to work with state regulatory agencies to ensure “equitable access of psychedelic therapy for all patients regardless of income status, insurance plans, no insurance or other disparity-limiting factors”. Belouin is a captain of the US Public Health Service and senior science policy advisor with the Substance Abuse and Mental Health Services Administration (SAMHSA), so his recommendations gives hope that psychedelic reform will be expedited through federal engagement.